18 results
6-K
EX-99.1
CLYYF
Celyad Oncology SA
5 Aug 22
Celyad Oncology Reports First Half 2022 Financial Results and Recent Business Highlights
6:11am
changes, both of which were partially offset by the decrease in clinical activities resulting from the Phase 1b CYAD-101-002 (KEYNOTE-B79) trial which
6-K
EX-99.2
CLYYF
Celyad Oncology SA
4 Aug 21
Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
4:01pm
subject to capitalization and to be offset against future capital raises have increased for an amount of €0.4 million. This increase is compensated … Immunicy) recognized in 2021 for €1.3 million. The decrease compared to year-end 2020 is mainly related to this convention and is partially offset
CORRESP
CLYYF
Celyad Oncology SA
3 Jun 21
Correspondence with SEC
12:00am
concerns that characterizing €172.3 million of capital contributed by shareholders to offset accumulated deficit is a faithful representation … TO OFFSET ACCUMULATED LOSSES
[...]
The Commission is of the opinion that, in general, internal movements in equity capital which do not affect
UPLOAD
CLYYF
Celyad Oncology SA
20 May 21
Letter from SEC
12:00am
that
characterizing 172.3
million of capital contributed by shareholders to offset
424B5
wnxaw6v
7 Jan 21
Prospectus supplement for primary offering
7:28am
424B5
u35il893dksj7f5zhr
11 Sep 20
Prospectus supplement for primary offering
5:13pm
F-3
zqtobkdshjc29z8zn7vj
28 Aug 20
Shelf registration (foreign)
4:02pm
6-K
EX-99.2
uy5mi
7 Aug 20
Celyad Oncology Reports Half Year 2020 Financial Results and Second Quarter Business Highlights
7:35am
6-K
EX-99.2
v13e6o6z
23 Aug 19
Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights
7:53am
20-F
edxgznth
8 Apr 16
Annual report (foreign)
12:00am
- Prev
- 1
- Next